EM – Eurofins, Qiagen are strengthening the rapid detection of the latest SARS-CoV-2 variant B.1.1529

0

Eurofins’ GSD NovaType Select P681H can distinguish variant B.1.1.529 from the currently dominant Delta variant

Researchers have identified a new SARS-CoV-2 variant with an alarmingly high number of mutations in the spike protein. The variant first identified in Botswana in November 2021 is spreading rapidly across South Africa. The variant contains more than 30 mutations to the spike protein.

Via Gold Standard Diagnostics Europe, Eurofins offers the toolset for quick identification of variant B.1.1.529. GSD NovaType Select is a range of RT-PCR assays for the specific detection of mutations in the SARS-CoV-2 genome in about 1 hour, much faster than genome sequencing methods.

On the other hand, QIAGEN has its SARS-CoV-2 PCR -Tests successfully checked for the genetic mutations of the variant with the scientific name B.1.1.529. The assessment was based on the data available in the public databases GISAID and GenBank.

“The best way to fight the global COVID-19 pandemic is a combination of comprehensive vaccination programs, rigorous testing with gold standard PCR tests and aggressive monitoring of new variants, ”said Dr. Davide Manissero, MD, Chief Medical Officer of QIAGEN NV.

Ashirwad Bungalow, First Floor, 36 / A / 2, S.No. 270, Pallod Farms, Near Bank of Baroda, Baner Road, Pune, Maharashtra, India 411045Mob: 91-9579069369

Keywords:

Severe acute respiratory syndrome,Coronavirus,Severe acute respiratory syndrome, Coronavirus,,covid reinfection,covid,covid vaccine,vaccine,covid variant,,,,,